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Simple Summary: Despite many recent advances in imaging and epidemiological data analysis,
musculoskeletal injuries continue to be a welfare issue in racehorses. Omics studies describe the
study of protein, genetic material (both DNA and RNA, including microRNAs—small non-coding
ribonucleic acids) and metabolites that may provide insights into the pathophysiology of disease
or opportunities to monitor response to treatment when measured in bodily fluids. As these fields
of study are scientifically complex and highly specialised, it is timely to perform a review of the
current literature to allow for the design of robust studies that allow for repeatable work. Systematic
reviews have been introduced into the medical literature and are a methodological way of searching
for relevant papers followed by critical review of the content and a detection of biases. The objectives
of the current systematic review were to identify and critically appraise the literature pertaining to
microRNA (miRNA) and their target genes that are correlated with stress fractures in racehorses and
humans. The object was to define a panel of miRNAs and their target genes as potential biomarkers
in either horses or human subjects. The online scientific databases were searched and a reviewed was
performed according to preferred reporting items for systematic reviews and meta-analyses (PRISMA)
guidelines. MicroRNA profiling studies in horses continue to emerge, but as of yet, no miRNA profile
can reliably predict the occurrence of fractures. It is very important that future studies are well
designed to mitigate the effects of variation in sample size, exercise and normalisation methods.
Abstract: Despite many recent advances in imaging and epidemiological data analysis, musculoskele-
tal injuries continue to be a welfare issue in racehorses. Peptide biomarker studies have failed to
consistently predict bone injury. Molecular profiling studies provide an opportunity to study equine
musculoskeletal disease. A systematic review of the literature was performed using preferred report-
ing items for systematic reviews and meta-analyses protocols (PRISMA-P) guidelines to assess the use
of miRNA profiling studies in equine and human musculoskeletal injuries. Data were extracted from
40 papers between 2008 and 2020. Three miRNA studies profiling equine musculoskeletal disease
were identified, none of which related to equine stress fractures. Eleven papers studied miRNA
profiles in osteoporotic human patients with fractures, but differentially expressed miRNAs were
not consistent between studies. MicroRNA target prediction programmes also produced conflicting
results between studies. Exercise affected miRNA profiles in both horse and human studies (e.g.,
miR-21 was upregulated by endurance exercise and miR-125b was downregulated by exercise).
MicroRNA profiling studies in horses continue to emerge, but as yet, no miRNA profile can reliably
predict the occurrence of fractures. It is very important that future studies are well designed to
mitigate the effects of variation in sample size, exercise and normalisation methods.
Keywords: microRNA; repetitive load injury; bone; biomarker; RNA-seq; SNP
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1. Introduction
Musculoskeletal injuries in racehorses are common and associated with potential
welfare issues. In a recent meta-analysis, the pooled incidence of catastrophic muscu-
loskeletal injury was 1.17 per 1000 race starts [1]. At least one fatal outcome was reported
at 21.5% of National Hunt events, with bone injuries being the most common [2]. The
majority of deaths reported in this study resulted from injuries to bone (77.8%), and these
predominantly involved the distal limb, with the third metacarpal or metatarsal as the most
commonly affected structure [2]. Similarly, in flat racing, the majority (77%) of fatalities of
Thoroughbreds in Great Britain were associated with a bone injury [3]. Early detection of
incomplete fractures can be difficult, and whilst imaging represents the frontline approach
to the screening of racehorses, there is currently no consensus about the specific interpreta-
tion of various imaging modalities including radiography, nuclear scintigraphy, computed
tomography, magnetic resonance imaging and positron emission tomography [4].
Stress fractures arise because of an imbalance between damage accumulation and
targeted repair at predictable sites of repetitive bone injury. Despite the progress in ad-
vanced imaging, micro-CT [5] and MRI [6] have failed to predict why certain levels of bone
densification and microdamage that lack targeted repair go on to propagate to complete
fracture in some individuals, yet the same levels are tolerated by others [7].
Omics technologies, genomics, transcriptomics, proteomics and metabolomics repre-
sent the study of the molecules, DNA, RNA, protein and metabolites, respectively. Genetic
association studies aim to identify if a certain gene (DNA) controls the phenotype of a
particular disease. Transcriptomic studies use next generation sequencing to identify if
messenger RNA (mRNA) influences a particular disease. MicroRNAs (miRNAs) are small
non-coding RNA molecules that are able to influence post-transcriptional gene expression.
MicroRNAs have been proposed as potential diagnostic and prognostic biomarkers [8,9] in
many diseases, and numerous miRNAs have been shown to be dysregulated in various
different types of cancers as oncogenes or tumour suppressor genes [10]. In addition to
their potential as biomarkers, miRNAs are being evaluated for their use as therapeutics in
some cancers and in treating hepatitis C. Several miRNA-targeted therapeutics in humans
have reached clinical trials, including a tumour suppressor miRNA-34a mimic in Phase I
clinical trials [11,12] and miR-122 anti-miRNA in Phase II clinical trials for treating hepatitis
C infection [13].
As circulating miRNAs have been identified as potential biomarkers of fractures in os-
teoporosis [14–18] and are beginning to be evaluated in equine orthopaedic disease [19–24],
the analysis of circulating miRNAs represents an exciting opportunity to study muscu-
loskeletal health, yet currently, there are no standardised pre-analytical, analytical and
post-analytical guidelines to allow for comparison between studies. It is therefore timely to
conduct a review of the literature. Whilst the aetiopathogenesis of equine stress fractures
secondary to repetitive loading is clearly different to that of osteoporotic stress fractures, it
was hoped that parallels in study design and analysis could be drawn. The authors chose
to consider both equines and humans, as both species sustain stress fractures [25] and their
bones have been shown to heal in situ without removal of the damaged domain [26].
Systematic reviews use explicit methods to identify, select, appraise and synthesise
results from similar but separate studies to identify high-quality evidence and highlight
gaps in the current research. Scoping reviews are essential where there is a large and
diverse evidence base, to provide a broad overview of the current evidence and to identify
areas suitable for more detailed evaluation in a systematic review. Currently there are
only two narrative reviews of miRNA relating to veterinary orthopaedics [27,28], and
no published systematic reviews or scoping reviews pertaining to stress fractures. There
are a range of different frameworks that have been developed to optimise the process of
systematic reviews. Preferred reporting items for systematic reviews and meta-analyses
(PRISMA) is widely accepted as the methodological framework for systematic reviews
and is recommended by many journals [29,30]. PRISMA provides an evidence-based
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minimum set of items that should be evaluated and reported, and their resources include a
standardised checklist and flow diagram.
It has been recommended that miRNA–RNA interactions should be validated in appro-
priate biological systems [31]. Analysis of miRNA–target interactions has been performed
with respect to bone using the following approaches: (1) target prediction programmes
followed by mRNA detection in bone tissue [17]; (2) correlations of differentially expressed
miRNAs with bone turnover markers [32]; (3) transfection of cells with miRNA and as-
sessment of in vitro osteogenic potential, such as bone alkaline phosphatase assays and
Alizarin red staining [33]; (4) treatment of mice with an agomir of the miRNA of interest
and an evaluation of bone density [18].
The objectives of this review are to (1) make recommendations regarding blood
sampling for miRNA studies with respect to the timing of feeding, exercise and haemolysis;
(2) summarise the relevant omics data pertaining to stress fractures in horses and humans;
(3) define and compare the panels of miRNA biomarkers and their miRNA targets identified
in studies of osteoporotic fractures in humans to provide methodological insights for
equine research.
2. Materials and Methods
2.1. Protocol and Registration
The review followed the methodology described in the Cochrane handbook for sys-
tematic reviews and the PRISMA statement for reporting systematic reviews and meta-
analyses [29,30]. This protocol was modified based on previously published systematic
review papers [34,35]. The preferred reporting items for systematic reviews and meta-
analyses protocols (PRISMA-P) checklist is presented in Supplementary Table S1. The
intervention for this scoping and systematic review was stress fractures in horses and the
outcome under consideration was the concentration of serum/plasma miRNA in horses.
As no literature was identified measuring miRNA in horses with stress fractures, the
intervention was broadened to include stress fractures in humans. Stress fractures in
horses occur frequently in young athletes during racing or training. Similar injuries also
occur in humans, especially elite athletes or military recruits. Since there are only limited
miRNA studies in horses, core findings in systematic human studies could also be valuable
for a better understanding of the horse studies. Consequently, the outcomes included
plasma/serum miRNA concentration in horses and humans. Widening the search for
this systematic review was considered appropriate, as stress fractures that occur in young
equines also occur in elite athletes and military recruits [25]. When the literature was
searched for stress fractures in humans and horses, again there was a paucity of studies. As
the objectives of this review included making recommendations regarding blood sampling
for miRNA studies with respect to timing of feeding, exercise and haemolysis, the search
inclusion criteria were further broadened to include omics studies in normal exercising
horses and those with musculoskeletal disease.
2.2. Synthesis of Outcomes for the Systematic Review
The three primary outcomes were to identify (1a) changes microRNAs/peptide anal-
ysis/gene expression related to musculoskeletal injuries in horses, (1b) microRNAs and
their targets in response to exercise and mechanical loading in horses and humans and (1c)
genetic association studies related to stress fractures in horses and young adults (e.g., ath-
letes/military recruits) equivalent to equine stress fractures. The secondary outcomes were
to analyse miRNA and their targets related to osteoporotic fragility fractures in humans.
2.3. Eligibility Criteria
We included randomised controlled trials (RCTs), and cohort, case-control and cross-
sectional studies. We excluded case series, case reports, narrative reviews and textbook
chapters. Study definition and categorisation were based on the Joanna Briggs Institute (JBI)
reviewer’s manual and methods for the development of the National Institute for Health
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and Care Excellence (NICE) public health guidance. A randomised controlled trial (RCT) is
a study where participants are randomly allocated to receive either the intervention or the
control. A quasi-experimental study or non-randomised controlled trial is a study where
participants are allocated to receive either the intervention or the control, but the allocation
is not randomised, an approach often called a controlled before-and-after or a time-series
study. A cohort study is an observational study in which a group of people or animals
(cohort) are observed over time in order to see who develops the outcome longitudinally. A
case-control study is a study where the investigator selects people or animals who have an
outcome of interest (e.g., disease) and others who do not (controls), and then collects data to
determine previous exposure to possible causes. A cross-sectional study is an observational
study in which the source population is examined to see what proportion has the outcome
of interest, or has been exposed to a risk factor of interest, or both [36,37]. A study was
included if the full text could be obtained from any of the University of Edinburgh libraries




The following databases were searched for this study:
• Medline In-Process and Non-Indexed Citations and Ovid MEDLINE: 1946–present;
• WEB of Science (Core Collection: Citation Indexes): 1950–present;
• SCOPUS: 1966–present.
2.4.2. Search Terms
For the horse studies, the following search terms were utilised for each of the respec-
tive databases:
Medline:
horse* OR equine* OR equus* OR racehorse* OR Thoroughbred* AND Fracture* OR
fractures* OR catastrophic* OR stress fracture* OR injury* OR orthopaedic* OR bone* OR
musculoskeletal* AND miRNA* OR microRNA* OR small RNA* OR RNA-seq* OR GWAS*.
WEB of Science:
TS = (horse* OR equine*) AND TS = (fracture* OR catastrophic* OR stress fracture*
OR injury* OR orthopaedic* OR bone* OR musculoskeletal*) AND TS = (miRNA* OR
microRNA* OR small RNA* OR RNA-seq* OR GWAS*).
SCOPUS:
TITLE-ABS-KEY (horse* OR equine* AND fracture* OR catastrophic* OR stress fracture*
OR injury* OR orthopaedic* OR bone* OR musculoskeletal* AND miRNA* OR microRNA*
OR small RNA* OR RNA-seq* OR GWAS*) AND (LIMIT-TO (LANGUAGE, “English”)).
For the human studies, the following search terms were utilised for each of the respec-
tive databases:
Medline:
Human* OR athlete* OR military recruit* AND fracture* OR stress fracture* OR fatigue
fracture* AND miRNA* OR microRNA* OR small RNA* OR RNA-seq*.
WEB of Science:
TS = (human*) AND TS = (fracture* OR stress fracture* OR fatigue fracture*) AND TS
= (miRNA* OR microRNA* OR small RNA* OR RNA-seq*).
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SCOPUS:
TITLE-ABS-KEY (human* OR athlete* OR military recruit* AND stress fracture* OR
fatigue fracture* AND miRNA* OR microRNA* OR RNA-seq* OR GWAS*) AND (LIMIT-
TO (LANGUAGE, “English”)).
2.5. Study Selection
A primary literature search of the databases was conducted using the search terms out-
lined previously. The results of each search were downloaded into bibliographical software
EndNote X9 (Thomson Reuters). Duplicates were deleted within EndNote. Publications
were then assessed through three stages: review of titles for suitable publications, review
of abstracts against inclusion and exclusion criteria and review of the full publications.
All titles within the EndNote library were examined and their abstracts were reviewed.
Ambiguous titles were retained for further review at the next stage (review of abstract).
Abstracts from these publications were then independently assessed by reviewers for
agreement with the inclusion and exclusion criteria for each of the primary and secondary
outcomes (Supplementary Tables S2–S5). Any publications which were ambiguous were
retained and reviewed in the next step (review of the full publication by SL and MB). The
full text of the final publication confirmed eligibility for this review and progressed to data
collection and quality appraisal (Figure 1).
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2.6. Data Collection Process/Data Items
The final full publications and methodological features were recorded on the detailed
data extraction form (Supplementary Tables S6–S10) based on a data collection form
by Cochrane Effective Practice and Organization of Care (EPOC). This was carried out
independently by one author (SL).
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2.7. Quality Appraisal and Risk of Bias in Individual Studies
Included studies were qualitatively assessed by two independent reviewers based on
the JBI critical appraisal checklist. Cumulative evidence of each paper was assessed by two
independent reviewers (SL and MB) based on the grading of recommendations, assessment,
development and evaluations (GRADE) system [38] and vetGRADE system [39] for human
and equine studies, respectively. Quality appraisals were assessed by two investigators (SL
and MB). When both investigators agreed to each criterion, “yes” was recorded, otherwise,
“unclear” or “no” was recorded. The risk of bias was incorporated alongside the reporting
of results within the results section of the article.
3. Results
3.1. Study Selection
The bibliographic searches performed between 24 April 2020 and 7 May 2020 identified
201 and 153 publications in horse and human studies, respectively, after the removal of
duplicates. A review of the titles and abstracts was performed against the inclusion and
exclusion criteria. Overall, 51 horse and 40 human studies were selected on the basis of
their relevance. A further full text review was carried out, which excluded articles for
various reasons according to our inclusion/exclusion criteria (Figure 1).
A total of 21 horse studies and 19 human studies met the defined inclusion/exclusion
criteria and were assessed with the JBI critical appraisal tools. The PRISMA 2009 flow
diagram of the study selection is reported in Figure 1. Data was summarised in a narrative
way because of the wide heterogeneity of the study population, study design and analytical
methods, it was not possible to perform meta-analysis of data. Determining of differentially
expressed miRNAs and genes was based on the results of statistical analysis where the P
value, adjusted P or false discovery rate (FDR) value was less than 0.05, depending on the
tests carried out. Only significantly differentially expressed miRNAs and their targets were
highlighted in cross-comparison studies.
3.2. Study Characteristics
The data extracted from the study characteristics consisted of the year of the study,
study design (Supplementary Table S6), inclusion and exclusion criteria (Supplementary
Table S7) sex and sample source (Supplementary Table S8), methods (Supplementary
Table S9) and results (Supplementary Table S10). The publications included were published
between 2008 and 2020. For primary outcome 1a, where 12 papers were reviewed, the most
common study designs were cohort studies (4) followed by case-control studies (3) and
cross-sectional studies (3), a quasi-experimental study (1) and a randomised controlled
trial (1). For primary outcome 1b, where 11 papers were reviewed, there were 10 quasi-
experimental studies and 1 randomised controlled trial. For primary outcome 1c, where six
papers were reviewed (five human and one horse) there were six case-control studies. For
the secondary outcome, where 11 human studies were reviewed, 8 were cross-sectional
studies, 2 were case-control studies and 1 was a cohort study.
The horse study population recruited included horses who visited veterinary hospitals
(11 studies), healthy horses (8 studies) and post-mortem material (2 horse studies). The
sample size of horse studies varied; seven studies had sample sizes of less than 30, nine
studies ranged from 30 to 100 and five larger studies had sample sizes ranging from 111 to
529. The mean or median reported age for horses was most commonly from 2 to 7 years old
(13 studies), 2 studies did not provide data, 5 studies included horses older than 7 years of
age and 1 study reported a mean age of 2 or less. Information of breed or type of horses
involved was reported for all studies, with Thoroughbred being the most common type of
breed (nine studies). Horse sex was not reported in 5 studies, was balanced in 15 studies
and 1 study included only male horses. There were specific exclusion reasons relating to
technical issues or confounding disease in 12 horse studies (Supplementary Table S11).
The human patients were referred to hospital (17 human studies) and healthy partic-
ipants (2 human studies). Human studies also varied in scale; four studies had sample
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sizes less than 30, seven studies ranged from 30 to 100 and eight studies had samples sizes
greater than 100. The mean or median reported age for 8 human studies was relatively
young, ranging from 20 to 30 years old, while 11 osteoporotic fracture studies involved
older individuals ranging from 40 to 80 years old. Human studies revealed more sex bias
due to the study population (e.g., military recruits, sports elites, pre- or postmenopausal
osteoporotic patients); 6 studies included only male or majority male subjects, 10 studies
had a majority of female subjects and 3 studies were of mixed sex. There were specific
exclusion reasons relating to technical issues or confounding disease in 14 human studies
(Supplementary Table S12).
3.3. Quality Appraisal and Risk of Bias
All included studies met at least 60% criteria out of total criterial for each study.
For primary outcome 1a there was one horse randomised controlled trial study [21],
when assessed using the JBI critical appraisal tool for randomised controlled trial studies
(Supplementary Table S13), the study met 12/13 criteria with the exception of criterion 4
(participants blind to treatment assignment). Of the four cohort studies for outcome 1a,
one study [40] met all criteria, one study [41] met 10/11 criteria, except for criterion 2
(clearly defined measurement of exposure) or criterion 7 (reliable measurement) and two
studies [42,43] met 9/11 criteria, except for criterion 6 (free of the outcome at the start of the
study) or criterion 10 (strategies to address incomplete follow-up). Of the three case-control
studies assessed using the JBI critical appraisal tool for case-control studies (Supplementary
Table S13) one study [20] met 9/10 criteria, one study [44] met 8/10 criteria, except for
criteria 6 (confounding factors) and 7, or criteria 7 and 9. One case-control study [45] met
7/10 criteria, except for criteria 4 (validity of exposure measurement), 6 and 7. Two [46,47]
of the three cross-sectional studies met all the criteria of the JBI critical appraisal tool for
cross-sectional studies; the other study [48] met 5/8 criteria, the exception being criteria 4
(standard measurement), 5 and 6. The quasi-experimental study met all 10 criteria [19].
For primary outcome 1b, there was one human case-control study, reported by San-
soni et al. (2018) [49] that met 9 out of 13 criteria, the exceptions being criteria 2, 4, 5 and
6 (outcome assessors blind to treatment assignment). Overall, 10 studies were assessed
using the JBI critical appraisal tool for quasi-experimental studies (Supplementary Ta-
ble S13). Five studies [50–53] met all 10 criteria, six studies [54–59] met 8/9 criteria, with
the exception of criterion 4 (control). For primary outcome 1c, there were six case-control
studies [60–65] that met 9 out of 10 criteria. For the secondary outcome, eight cross-sectional
studies [16,17,32,33,66,67] met all criteria and one study [68] met 7/8 criteria, the exception
being criterion 6 (strategy to deal with confounding factors). One cross-sectional study [69]
met 6/8 criteria, the exceptions being criteria 5 (define confounding factors) and 6. The two
case-control studies [18,70] met 9/10 criteria. The cohort study [71] met 10/11 criteria, the
exception being treatment groups were not treated identically (Supplementary Table S13).
3.4. microRNAs/Peptide Analysis/Gene Expression Related to Musculoskeletal Injuries in Horses
Reviewing miRNAs and their targets to equine musculoskeletal injuries identified
12 publications including 2 miRNA candidate studies, 1 miRNA profiling study, 2 mRNA
profiling studies and 7 biomarker studies (horse peptide biomarker studies prior to 2008
were not reviewed) (Supplementary Table S14). The three miRNA studies reported on
diverse disease processes, tendon injury, laminitis and osteochondrosis, and unsurprisingly,
did not report on the same miRNAs. One randomised controlled trial that scored highly
in the quality appraisal and risk of bias reported a decrease in miRNA-29a levels in
tendon injury, yet it should be remembered that participants were not blinded to treatment
assignment. The decrease in miRNA-29a was confirmed using an miR-29a mimic in equine
tenocytes, which selectively targeted to COL3A1 encoding type III collagen [21]. Another
study reported that levels of miR-23b-3p, miR-145-5p and miR-200b-3p increased in acute
laminitis [20]; however, the case-control study of acute laminitis may have been subjected to
age biases as the cases were mature horses with laminitis and the controls were immature
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horses. Targets of these miRNAs were linked to the glutamatergic pathway, which is
associated with the major excitatory neurotransmitter released in synapse of the pain-
transmitting afferent neurons. Combining the pain-deregulated miRNAs (miR-145-5p
and miR-200b-3p) resulted in a positive correlation with horse grimace scores in acute
laminitic horses. A further study, with a small sample size, reported a decrease in levels
of miR-126-5p, miR-135a-5p, miR-451 and miR-486 in cartilage and an increase in levels
of miR-1249 and miR-197 in bone from three 10 month old foals with osteochondrosis
compared to three control foals [19].
In terms of peptide biomarker candidate (Supplementary Table S14) studies for frac-
ture/injury risk factors, three studies [42,43,45] reported a decreased serum level of carboxy-
terminal telopeptide fragments of type II collagen (CTX-II) in in 2–3 year old Thoroughbreds
following carpal or fetlock joint injuries. However, arthroscopic scores were not correlated
with synovial fluid or serum CTX-II in one of these studies [45]. Furthermore, as cohort
studies [42,43] the results could be subject to selection bias as a result of horses being
lost to follow-up. A separate paper found the two biomarkers CTX-I and bone alkaline
phosphatase were not accurate biomarkers for bone fragility syndrome represented by
scapula stress fractures [44]. also reported that there was no significant difference between
injury and control at the baseline or entry time point. In a longitudinal study, the greatest
change of four biomarkers occurred 4–6 month prior to injury: a decrease of articular
cartilage biomarkers, glycosaminoglycan (GAGs) and aggrecan chondroitin sulfate 846
epitope (CS486), and an increase in bone biomarkers, CTX-I and osteocalcin [40]. In one
recent study [43], decreased osteocalcin and CTX-I, representing altered bone turnover,
were specific for injured horses in a population of Polish racehorses in contrast to findings
in a North American population.
3.5. microRNAs and Their Targets in Response to Exercise and Mechanical Loading in Horses
and Humans
A review of miRNAs and their targets in response to exercise and mechanical load-
ing in horses and humans identified 11 publications including 5 horse miRNA profiling
studies [50,53,55–57], 1 human miRNA profiling study [49], 2 human miRNA candidate
studies [52,54], 2 horse mRNA profiling studies [51,59] and 1 horse mRNA candidate
study [58] (Supplementary Table S14). Overall 10 of the 11 studies were quasi-experimental
studies, e.g., before and after the intervention (exercise), where miRNAs were measured
at two points in time. These were not randomised, and therefore, interpolation should be
carried out cautiously to similar populations. The following results should be interpreted
with caution, as many of the studies only scored as low on the Grade/vetGRADE pyramid.
The three horse miRNA studies [53,56,57] and one human miRNA study [52] reported
an increase in miR-21-5p levels after exercise; although, a further human study [49] reported
stable expression of miR-21-5p, even after exercise. These horse studies also reported an
increase in levels of members of the let-7 family in response to exercise [53,56,57]. A
decrease in levels of miR-16 following an 160 km endurance competition was reported in
two of these horse studies [56,57], and a gradual decrease in miR-16 levels followed by
explosive strength training was also reported in one human study [52]. Analysis of the
predicted genes targeted by miRNAs increased upon exercise (e.g., miR-1, miR-133 and
miR-206) [50,54], suggesting the involvement of the muscle remodelling pathway (IGF1R,
EGFR, PURB, TAGLN, TMOD2, LASP1 and SGCD) [50]. Two mRNA profiling studies in
Arabian horses [58,59] reported that race training or competing in flat races induced an
osteoclast differentiation pathway involving CTSK, IL6ST, NFATc1, CLEC5A and VAV3.
3.6. Genetic Association Studies Related to Stress Fractures in Horses and Young Adults (e.g.,
Athletes/Military Recruits) Equivalent to Equine Stress Fracture
Reviewing genetic association studies related to stress fractures in young adults
(18–35 years) identified 5 human publications and 1 horse paper (Supplementary Table
S14). All the identified studies were case-control studies and as such may be subject
to selection bias. Four genetic studies [63,65,72,73] focused on logical candidate genes
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involved in bone formation and bone-associated disorders and reported that vitamin D
receptor (VDR) SNPs are correlated to stress fractures; homozygotes of the rare allele of
VDR SNPs are involved in the multiple stress [64], C–A haplotypes in VDR are involved
in a 3.0-fold higher risk of stress fracture [63] and the F and B alleles FokI in VDR are
associated with a 2.7-fold and a 2.0-fold increase in risk of stress fractures in military
personnel [61]. One genome-wide association study [62] reported several different novel
variants of genes including G protein-coupled receptor kinase 4 (GRK4), Nebulin (NEB),
solute carrier family 6 member 18 (SLC6A18), leucine rich repeat containing 55 (LRRC55),
sialic acid-binding Ig-like lectin 12 (SIGLEC12) and extracellular leucine rich repeat and
fibronectin type III domain containing 2 (ELFN2) were significantly different in synovial
fluid(SF) cases of Israeli soldiers compared with controls. The only horse study, by Blott
et al. (2014) [60], that looked at risk of fracture in Thoroughbred racehorses (269 fractures
were used and 253 controls) reported that loci in chromosome 1 and 18 were significantly
associated with fracture.
3.7. microRNAs Related to Osteoporotic Fragility Fractures in Humans
Reviewing miRNAs related to osteoporotic fragility fractures in humans identified
11 publications, including 7 miRNA candidate studies [32,66–71] and 4 miRNA profiling
studies [16–18,33] (Supplementary Table S7). The osteoporotic fragility fracture studies do
not consistently identify differentially expressed (DE) miRNAs, for example, miR-21-5p
was reported to be upregulated in three papers [17,69,70], unchanged in one paper after
correction for age [68], downregulated in a further paper [67] and not measured or not
significantly different in the remaining papers [18,32,33,71]. A further miRNA, miR-19b,
that regulates the osteogenic transcription factor Runx2 was differentially expressed in four
of the nine osteoporotic fracture miRNA studies, upregulated in three papers [32,67,71],
but downregulated in one paper [18]. Mandourah et al. (2018) [16] also reported that,
in combination, miR-122-3p and miR-4516 were significantly decreased in osteoporotic
groups compared to osteopaenic groups and controls, but individually were of less value in
diagnosing osteoporosis (AUC = 0.666 and AUC = 0.727). Feichtinger et al. (2018) reported
three downregulated differentially expressed miRNAs, miR-29b-3p, miR-324-3p and miR-
550a-3p, that were significantly associated to dynamic histomorphometric parameters of
bone formation.
Profiling studies frequently utilise a panel of selected potential differentially expressed
miRNAs as biomarkers in order to increase the sensitivity and specificity to detect bone
fragility fractures. One of the earlier validation studies [17] that used miRNA PCR ar-
rays identified miR-21, miR23a, miR-24, miR100 and miR-125 as a panel of upregulated
miRNAs in both serum and bone of osteoporotic patients (20 osteoporotic patients vs.
20 non-osteoporotic controls). A larger, more recent validation study looking at osteo-
porotic patients with and without fracture found no association between 32 miRNAs
and bone turnover markers, bone mineral density and high-resolution peripheral quan-
titative computed tomography. Furthermore, there was no association between baseline
serum miRNA expression and prospective incident fracture in 108 women compared to
469 women without fracture [68]. Zarecki et al. [69] found seven upregulated miRNAs
(miR-375, miR-532-3p, miR-19b-3p, miR-152-3p, miR-23a-3p, miR-335-5p and miR-21-5p)
in patients with vertebral fractures [69]. A further validation study did find miR-29b-3p,
miR-324-3p and miR-550a-3p to be correlated with bone histomorphometry and microar-
chitecture [66], and this work was used as a basis for a panel of 19 miRNAs that predicted
more fracture events than the fracture risk assessment tool (FRAX) index [71] in a small
cohort of women. The candidate and validation studies described in this section did not
show consistency in the miRNA panels to differentiate between osteoporotic women with
and without fracture. Direct study comparisons are difficult due to differences in sample
size, study population and study design.
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3.8. miRNA Target Analysis Related to Osteoporotic Fragility Fracture in Humans
Of the 10 studies that evaluated osteoporotic fragility factors, 4 used miRNA target
prediction programmes [16–18,69]. Seeliger et al. (2014) [17] identified reduced PDCD4
and c-FOS influenced by miR-21, reduced Runx2 influenced by miR-23a, miR-24 and
miR-27 and reduced BMPR2 influenced by miR-100 in osteoporotic patients. Mandourah
(2018) [16] found miR-122-5p and miR-4516 to be correlated with fragility fracture and
use of the target prediction programmes, miWalk, miRanda, RNA22 and Targetscan, with
the search term osteoporosis, which suggested that eight mRNAs, including BMP2K,
FSHB, IGF1R, PTHLH, Runx2, SPARC, TSC22D3 and the vitamin D receptor, would be
potential targets of both miR-122-5p and miR-4516. Because targets were predicted by
bioinformatically, further experimental validation (e.g., qPCR, in vitro assay) is warranted.
Two more recent papers [18,69] found differential expression of miR-19b, but, although
both used similar target prediction programmes including DIANA (https://bio.tools/
DIANA-microT (accessed on 28 March 2021)), they identified different potential target
genes for this miRNA. Five studies attempted to correlate circulating miRNAs and bone
turnover markers [18,32,68–70]. Two studies used cell transfection experiments [18,33] and
one treated mice with an agomir [18].
4. Discussion
This review assessed the current evidence on, and feasibility of, using reported miR-
NAs and mRNA targets for potential diagnostic biomarkers to predict fractures. Very few
high-quality studies exist in the equine and human literature. In total, 21 equine studies
and 19 human studies were selected for this systematic review.
4.1. Key Findings
Objective (1): MiR-21 and miR-125b were frequently reported miRNAs affected by
exercise and mechanical loading in horses and humans. Blood for circulating miRNA anal-
ysis should be collected from fasted animals before exercise and samples with evidence of
haemolysis should be discarded. Objective (2): There were differentially expressed miRNA,
mRNA, peptide biomarkers or genetic associations reported as statistically significant
across the 40 papers. There was no consensus of miRNAs to predict musculoskeletal injury
in horses. Genetic association studies were often underpowered, were subject to bias and
were not sex specific. Objective (3): differentially expressed miRNAs and predicted targets
were not consistent between human osteoporotic fragility fracture studies.
The two blood fractions, plasma and serum, are valuable sources for the investigation
of potential biomarkers in various pathological conditions. Although they are usually
considered to be equivalent, several studies addressed how the type of blood fractions
(serum or plasma) influences the analysis of circulating miRNA and how their miRNA
content may significantly differ [74,75]. Plasma must be carefully separated from the red
blood cells or buffy coat in order to avoid cellular contamination. For serum this is not
the case due to the coagulation of the sample. It is still controversial which blood fraction
is the most reliable source. One study showed higher miRNA concentrations in serum
samples compared to the corresponding plasma samples using a qPCR platform, and this
was associated with miRNA from platelets, indicating that a coagulation process may
affect the spectrum of extracellular miRNA in blood [75]. Interference with polymerase
chain reactions has been reported for heparinised blood samples [76]. Furthermore, using
anti-coagulant heparin could complicate transcriptomic analysis because heparin may
inhibit RNA polymerase so that it causes inefficient mRNA synthesis and fluorophore
labelling [77]. Therefore, ethylenediaminetetra acetic acid (EDTA) is recommended when
collecting blood from horses for next generation sequencing. Another study demonstrated
that plasma from rats generated more aligned reads than serum from rats according to
high-throughput sequencing; however, these differences were not observed in human
samples [74]. In our experience, horse blood tends to form more fibrin clots due to a
prolonged clotting time and poor clot retraction, which fails to reliably obtain a high quality
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of serum. Caution must be taken when comparing miRNA data generated from different
sample types or measurement platforms.
All of the post-exercise plasma samples and the majority of the pre-exercise plasma
samples underwent haemolysis in one study [53], highlighting the need for standardised
quality control and sampling times in fit racehorses. No haemolysis was reported in pre-
or post-blood samples in 14 Arabians that were sampled within 30 min of completing a
130 km endurance event [56]. In contrast to the Thoroughbred study where EDTA tubes
were used, PAXgene Blood RNA tubes were used in the Arabian study. One in vitro study
identified miR-378 and miR-30c to be haemolysis independent and identified that miR-320
and miR 324-3p were associated with red blood cell contamination [78]. Several human
studies [16,32,69] controlled for haemolysis by checking a delta Cq between miR-23a and
miR-451 (>7 is an indicator of haemolysis). Faraldi et al. (2019) [79] also investigated four
different normalisation strategies to identify the best method for the most reliable results.
Interestingly, in this study, miR-320d was found to be the most stable reference gene for
circulating miRNAs in the study of sprint training in people. These authors also showed
that different normalisation strategies produced different results, hence highlighting the
importance of accurately choosing the most reliable normalisation methods in every in-
dividual experimental setting. The use of such techniques is considered advantageous
when assessing circulating miRNAs from fit Thoroughbred racehorses. An independent
validation set of animals confirmed that miR-21-5p, miR-181-5p and miR-505-5p are can-
didate molecules reflecting adaptation to exercise in endurance horses [56]. A separate
study of four Arabian horses, sampled pre- and post-endurance competitions (90 km)
using blood collected into EDTA tubes, was not in agreement with these findings and
identified miR-206, miR-208b and miR-1 as the most upregulated differentially expressed
miRNAs [50]. Levels of 12 circulating miRNAs (including miR-125b and miR-122-5p)
were elevated immediately after marathon running in middle-aged individuals [80]. In
addition to the effects of immediate exercise, human studies have evaluated the effects of
different types of exercise on circulating miRNAs. One human study evaluating circulating
miRNAs in endurance and strength athletes found that miR-222, miR-21 and miR-146a
were significantly elevated in the endurance athletes compared to the strength athletes [81].
There is increasing work demonstrating the influence of miR-21 on bone homeostasis,
the miR-21 knockout mouse showed impaired formation of the calvarial bone and in vitro
work has demonstrated a dual action of miR-21 on both osteoblasts and osteoclasts [82].
MicroRNA-21 has been shown to be a sensitive and specific marker for the early identifica-
tion of breast cancer in one meta-analysis [83], colorectal cancer in another meta-analysis [9]
and overexpression of miR-21 was reported in both prostate cancer and osteosarcoma stud-
ies [82]. Furthermore, miR-21 has been shown to be increased in experimental studies
during fracture repair in mice [84]. One candidate study [14] and two profiling stud-
ies [17,69] highlighted increased miR-21 as part of a profile of increased miRNAs in women
with osteoporotic fractures. Three further studies on osteoporotic fracture did not identify
increased miR-21 [15,16,18], highlighting the need for comparable sampling and processing
protocols. Increased miR-21 has also been correlated with reduced bone mineral density in
osteoporotic patients independent of sex [14].
There was no common miRNA reported in stress fracture/musculoskeletal injuries in
horses, possibly because of the limited number of studies. The plasma- and serum-derived
miRNA profile pattern in laminitic horses differed from the control; however, their miRNA
targets were related to pain-related genes in the glutamatergic pathway rather than bone-
related genes [20]. Injured tendon- [21], cartilage- and bone-derived miRNA profiling [19]
and their targets in horses were correlated to cartilage integrity (cell cycle, differentiation,
collagen production, energy production and metabolism and extracellular matrix structure)
and bone maintenance (osteoblasts and osteoclasts differentiation, energy production,
vesicle transport and growth factor signalling pathways). However, because of the very
limited studies in horses, extensive further study is required. Pacholewska et al. [85] has
compared miRNA expression in various normal tissues (abundance of miR-486 in serum
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and blood, miR-144 in bone, miR-20b in bone and liver, novel-miR-174, novel-miR-27,
novel-miR-634 in cartilage and miR-193 in liver) and identified tissues/breed-specific
miRNAs (let-7f in 30 Warmbloods, increase of miR-122 and decrease of miR-328 miRNAs
in 5 ponies).
Differentially expressed miRNAs and genes were defined on the basis of the results
of statistical analysis. Only significantly differentially expressed miRNAs and their tar-
gets were highlighted in cross-comparison studies. The miRNA target was validated
using a qPCR of tissues to detect levels of mRNA or combination of transcriptomic data,
metabolomic profiles or measurement of metabolites [49,56,57]. In vitro cellular validation
was only carried out in three papers [18,19,21].
Overall, 10 studies out of 23 miRNA studies including, 12 non-biased miRNA profiling
studies and 11 targeted miRNA candidate studies, carried out the validation of the findings
with an independent cohort. Of these, a non-biased miRNAs profiling study in humans
by Sun et al. [18] performed a comprehensive investigation of miR-19b involvement in
fracture risk by the identification of differentially expressed miRNA, and validation in an
independent cohort of the effect of miR-19b mimic or inhibitor and its target on osteoblastic
differentiation of human mesenchymal stem cells and mouse osteoblast, in vivo in mice.
Zarecki et al. [69] showed miR-21-5p interacts with the yes-associated protein (YAP), a
transcriptional factor that negatively regulates the Hippo pathway, which has a primary
role in osteoblast differentiation and also an emerging role in regulation of pre-osteoclast
proliferation and differentiation of osteoclast. Zarecki et al. further showed that miR-19b
influences the oestrogen signalling pathway and this was confirmed in a separate study
by the administration of the synthetic mimic of miR-19b (agomiR-19b) to ovariectomised
mice [18]. Whilst this specific miRNA is unlikely to be of importance in equine stress
fractures, these studies highlight the proof of the principal concept for miRNA target
interactions. Makitie et al. (2018) [15] reported that circulating miRNAs were significantly
different in the WNT1 mutation group, which leads to severe early-onset and progressive
osteoporosis. Of these differentially expressed miRNAs, miR-22-3p, miR-34a-5p and
miR-31-5p are known inhibitors of WNT signalling: miR-22-3p and miR-34a-5p target
WNT1 messenger RNA, and miR-31-5p is predicted to bind to WNT1 30UTR. This study
provided a close insight of miRNAs and their targets and their respective relations to
bone disorders.
Castanheira and their colleagues [23] revealed 22 differentially expressed synovial
fluid small non-coding RNAs from the metacarpophalangeal joints of early osteoarthritis
compared to the control, which may provide a potential usage of synovial fluid small
non-coding RNAs as molecular biomarkers for early disease in equine osteoarthritic joints.
Balaskas et al. [22] demonstrated 83 differentially expressed small non-coding RNAs be-
tween the young and old equine chondrocytes that were normal on gross appearance,
highlighting the importance of age-matched controls when planning miRNA studies. One
recent systematic review of tendon epigenetics [24] suggested that epigenetic mechanisms,
including changes of non-coding RNA, are important in predisposing ageing tendons to
injury. Sex has also been shown to influence gene expression including miRNA expres-
sion [86] and must therefore be carefully considered when planning any omics studies [87].
Blott et al. (2014) [60] reported loci in chromosome 1 and 18 were significantly as-
sociated with risk of fracture in Thoroughbred racehorses (269 fractures were used and
253 controls). Statistical significance was not reached for any of the SNP in the study
by Blott et al., and those authors suggested a sample size of >1000 would be necessary.
Additionally, the depth of the SNP chip used in the Blott et al. paper was modest by current
standards. Two of the human studies reviewed here identified the VDR FokI as a potential
SNP that may predispose individuals to fracture [63,64]. A recent systematic review and
meta-analysis (performed subsequent to the inclusion dates of the current work) of gene
association studies looking at fracture risk in physically active individuals suggested that
many of the studies were underpowered and did not reach the Hardy–Weinberg equilib-
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rium. Furthermore, reporting bias was described as moderate to critical in each of the
10 reviewed studies, including those reviewed here [88].
Raw data or omics data (e.g., microarray, small RNA-seq, RNA seq data, etc.) from
most of recent studies in this review were deposited in online databases, allowing for free
sharing and open exchange data. However, for best practice, establishing the relevant data
standards including clearly stated experiment descriptions, data exchange, terminology
standards and experiment execution standards must also be shared to maximise the utility
of existing data.
4.2. Limitations
The main limitation of this systematic review is the heterogeneity of the included
publications due to the lack of equine fracture omics research. Therefore, the search terms
were extended to include musculoskeletal injury, gene expression studies and human
studies. Stress fractures in equine athletes are thought to be equivalent to fatigue fractures
or stress fractures in elite human athletes or military recruits. There has been extensive
research on osteoporotic fractures in humans, particularly in the ageing population, and
a large number of studies have investigated miRNAs as potential biomarkers to predict
fractures. Within the 11 osteoporotic fracture publications reviewed, variations in specific
miRNAs analysed and different normalisation methods prevented a meta-analysis. Only a
small number of miRNAs and targets were consistently identified as affected by disease;
therefore, assessment of the potential of miRNAs as biomarkers for detection of fractures
requires further research. The reviewed work was not substantial enough to identify an
effect of age on miRNA expression and detection in horses, as many of the studies had too
small a sample size to detect the influence of age, as has been reported subsequent to the
literature search for this review [22–24].
4.3. Summary of Evidence
Following review of the current literature, blood for circulating miRNA analysis was
most frequently collected from fasting animals, pre-exercise. The degree of haemolysis
should be closely monitored such that any samples with haemolysis can be discarded.
Comparisons of recommended miRNA profiles between studies reported conflicting results,
suggesting there is currently no miRNA profile that can accurately predict fracture. Direct
study comparisons remain difficult due to differences in the sample size, study population
and molecular analysis techniques used.
5. Conclusions
This review highlighted the complexities of circulating miRNA analysis and genetic
association studies. The key considerations when planning a genetic association study
include a power calculation, sex-specific analysis and consideration of the effects of nu-
trition. In order to achieve high-quality, reproducible miRNA results, researchers must
strive to minimise differences caused by pre-analytical factors (fasting, exercise and diet),
analytical factors (whether the platform used next generation sequencing, miRNA array or
qPCR) and post-analytical factors (consideration of the most stable reference gene(s) for
individual studies). Despite a robust study design, including power calculations and a
large sample size of several human studies, a reliable panel of miRNAs to detect and/or
predict fracture occurrence was not identified.
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